OneMedNet (NASDAQ:ONMD - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a research report issued to clients and investors on Tuesday,Weiss Ratings reports.
Separately, Wall Street Zen upgraded OneMedNet to a "hold" rating in a research note on Friday, September 26th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of "Sell".
Read Our Latest Analysis on ONMD
OneMedNet Price Performance
NASDAQ ONMD traded up $0.11 on Tuesday, hitting $3.07. 2,209,987 shares of the company were exchanged, compared to its average volume of 6,391,317. The company's 50 day moving average price is $1.05 and its 200-day moving average price is $0.67. The firm has a market capitalization of $150.86 million, a P/E ratio of -27.99 and a beta of 0.99. OneMedNet has a twelve month low of $0.30 and a twelve month high of $4.22.
OneMedNet (NASDAQ:ONMD - Get Free Report) last issued its earnings results on Wednesday, August 13th. The company reported ($0.03) earnings per share for the quarter. The firm had revenue of $0.16 million during the quarter.
Institutional Investors Weigh In On OneMedNet
A hedge fund recently raised its stake in OneMedNet stock. Exencial Wealth Advisors LLC boosted its holdings in OneMedNet Corporation (NASDAQ:ONMD - Free Report) by 3.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,491,862 shares of the company's stock after purchasing an additional 45,448 shares during the period. Exencial Wealth Advisors LLC owned about 4.73% of OneMedNet worth $851,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.95% of the company's stock.
OneMedNet Company Profile
(
Get Free Report)
OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider OneMedNet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OneMedNet wasn't on the list.
While OneMedNet currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.